Back to dashboard
CommercialCoverageMedium impact

New policies

Blue Cross Blue Shield of Rhode Island·RI · Oncology, Pathology·Physician / Facility
Effective date
Jun 1, 2020
We identified it
Jun 19, 2026
Days to comply

Summary

Blue Cross Blue Shield of Rhode Island has created a new medical policy effective June 1, 2020, covering genetic expression assays in tumor tissue for determining prognosis in breast cancer patients. This policy will establish coverage criteria and billing guidelines for these specialized diagnostic tests.

Action Required

Action needed
By June 1, 2020: Billing team should review the full policy text on bcbsri.com under Medical Policy section to understand coverage criteria, documentation requirements, and billing procedures for genetic expression assays in breast cancer tumor tissue. Update billing workflows and ensure proper coding compliance for these diagnostic tests.